Overview
Low-grade gliomas (LGGs) of the brain are slow-growing neoplasms that primarily affect adults, though they can occur in children. These tumors originate from glial cells, typically oligodendrocytes or astrocytes, and are classified based on their histological characteristics and molecular profiles, such as IDH mutation status and chromosome 1p/19q codeletion. LGGs are clinically significant due to their potential for local invasion and, in some cases, progression to higher-grade gliomas. They often present with nonspecific symptoms like headaches, seizures, and cognitive changes, making early diagnosis challenging. Understanding the molecular underpinnings of LGGs, such as the roles of PANX2 and NFE2L2, is crucial for improving prognostic stratification and therapeutic approaches. This knowledge is vital in day-to-day practice for tailoring individualized treatment plans and monitoring disease progression. 125Pathophysiology
The pathophysiology of low-grade gliomas (LGGs) involves complex molecular alterations that drive cellular proliferation and survival. Key genetic mutations, such as those in the IDH1/2 genes, are frequently observed and are associated with a distinct metabolic profile characterized by the accumulation of 2-hydroxyglutarate (2-HG), which disrupts cellular differentiation and promotes tumorigenesis. Additionally, the involvement of pannexins (Panxs) adds another layer of complexity. Specifically, PANX2, a brain-specific channel predominantly expressed in neurons and neural progenitor cells, has been proposed to function as a potential tumor suppressor in LGGs. Downregulation of PANX2 has been linked to glioma genesis, suggesting that impaired channel function may contribute to tumor development by disrupting paracrine signaling and cellular homeostasis. Conversely, NFE2L2, a transcription factor involved in redox regulation, plays a role in modulating oxidative stress responses, which can promote cell proliferation and chemoresistance. Aberrant NFE2L2 expression correlates with immune infiltration and may influence the tumor microenvironment, affecting immune evasion mechanisms. These molecular pathways highlight the intricate interplay between genetic mutations, cellular signaling, and immune modulation in the pathogenesis of LGGs. 125Epidemiology
Low-grade gliomas (LGGs) predominantly affect adults, with an estimated annual incidence of approximately 5-10 cases per 100,000 people. They are less common in children but still represent a significant portion of pediatric brain tumors. LGGs show no strong sex predilection but exhibit variations in incidence based on molecular subtypes. For instance, IDH-mutant LGGs are more prevalent in adults, while pediatric LGGs often lack these mutations. Geographic distribution does not show significant variations, but certain genetic predispositions and environmental factors may influence risk. Over time, there has been an increasing recognition of molecular subtypes, leading to more refined diagnostic criteria and prognostic stratification. However, large-scale epidemiological studies are still evolving to fully capture trends and risk factors. 35Clinical Presentation
Low-grade gliomas (LGGs) often present with nonspecific symptoms due to their slow growth and variable location within the brain. Common clinical features include:
Headaches: Often persistent and may worsen over time.
Seizures: Particularly focal seizures, which can be the initial presenting symptom.
Cognitive Changes: Such as memory impairment, personality changes, or difficulties with executive function.
Neurological Deficits: Depending on the tumor location, patients may exhibit motor deficits, visual disturbances, or speech problems.
Behavioral Symptoms: Apathy, irritability, or behavioral changes can occur, especially in pediatric cases.Red-flag Features:
Rapid progression of symptoms.
New-onset seizures in older adults without prior history.
Significant cognitive decline over a short period.
Presence of focal neurological deficits that suggest mass effect or increased intracranial pressure.Early recognition of these symptoms is crucial for timely diagnosis and intervention. 35
Diagnosis
The diagnostic approach for low-grade gliomas (LGGs) involves a combination of clinical evaluation, imaging, and histopathological analysis:
Clinical Evaluation: Detailed history and neurological examination to identify symptoms and signs.
Imaging:
- MRI: Essential for visualizing tumor location, size, and characteristics. Contrast-enhanced MRI often shows characteristic features like infiltrative borders and peritumoral edema.
- Functional Imaging: Techniques like fMRI or PET scans may be used to assess tumor impact on brain function and metabolism.
Histopathological Analysis:
- Biopsy: Definitive diagnosis typically requires a stereotactic biopsy or surgical resection.
- Histological Criteria: Examination under the microscope for specific cellular features, such as nuclear atypia, mitotic activity, and the presence of gemistocytes.
- Molecular Testing: Essential for subclassification:
- IDH Mutation: Presence of IDH1/2 mutations is common in adult LGGs.
- 1p/19q Codeletion: Identified through FISH or SNP array analysis, indicating a more favorable prognosis.
- Other Markers: MGMT promoter methylation status, ATRX mutations, and TERT promoter mutations may also be assessed.Specific Criteria and Tests:
MRI Findings: Infiltrative margins, contrast enhancement, and peritumoral edema.
Biopsy Requirements: Stereotactic biopsy if surgical resection is not feasible.
Molecular Subtypes:
- IDH-Mutant: Common in adults; assess IDH1/2 mutations.
- IDH-Wildtype: Less common; consider alternative diagnoses like ganglioglioma or diffuse astrocytoma.
- 1p/19q Codeletion: Favorable prognosis; assess via FISH or SNP array.
Immunohistochemistry: GFAP, Olig2, and IDH1/2 protein expression to support diagnosis.
Differential Diagnosis:
- Radiosurgery Necrosis: History of prior radiation therapy.
- Lymphoma: B-cell markers, flow cytometry, and clinical context.
- Metastatic Lesions: Detailed imaging and systemic workup for primary cancer.(Evidence: Strong 35)
Differential Diagnosis
Radiosurgery Necrosis: History of prior radiation therapy and characteristic imaging findings.
Lymphoma: Presence of B-cell markers on immunohistochemistry and systemic lymphoma workup.
Metastatic Lesions: Detailed imaging and systemic evaluation for primary malignancies.
Vascular Malformations: Angiography or MRI angiography to differentiate from mass effect.
Infections (e.g., Abscess): Clinical context, imaging characteristics, and microbiological studies.(Evidence: Moderate 35)
Management
First-Line Treatment
Surgical Resection: Primary treatment for accessible tumors to achieve maximal cytoreduction.
Radiation Therapy: Generally reserved for progressive or symptomatic cases, especially in IDH-wildtype tumors.
- Dose: Typically 54-59.4 Gy in 30-33 fractions.
- Monitoring: Regular neurological assessments and MRI follow-ups.Second-Line Treatment
Chemotherapy: Often considered for IDH-wildtype LGGs or recurrent tumors.
- Temozolomide: Commonly used in IDH-wildtype cases.
- Dose: 50-75 mg/m2 daily for 5 days every 28 days.
- Monitoring: Periodic blood counts, renal function tests, and neurological evaluations.
- Carboplatin/Vincristine: Alternative regimens for specific subtypes.
- Dose: Tailored based on patient tolerance and response.
- Monitoring: Similar to temozolomide with additional cardiac monitoring.Refractory or Specialist Escalation
Targeted Therapy: Emerging role for targeted agents based on molecular profiles.
- IDH Inhibitors: Such as ivosidenib or enasidenib for IDH1/2 mutations.
- Dose: Ivosidenib 500 mg daily; Enasidenib 100 mg daily.
- Monitoring: Regular assessment of efficacy and adverse effects.
Immunotherapy: Investigational, particularly in combination with immune checkpoint inhibitors.
- PD-1/PD-L1 Inhibitors: Ongoing clinical trials; monitor for immune-related adverse events.
- Monitoring: Close clinical and radiological follow-up.Contraindications:
Surgical Resection: Significant comorbidities precluding surgery.
Radiation Therapy: Young age, critical location near eloquent brain areas.
Chemotherapy: Severe bone marrow suppression, renal or hepatic dysfunction.(Evidence: Strong 35)
Complications
Acute Complications
Seizures: Require immediate anticonvulsant management (e.g., levetiracetam, valproate).
Increased Intracranial Pressure: May necessitate osmotic diuretics (mannitol) or surgical intervention.Long-Term Complications
Neurocognitive Decline: Regular neuropsychological assessments and supportive therapies.
Radiation Necrosis: Late complication post-radiation; MRI monitoring and potential surgical intervention.
Secondary Malignancy: Long-term risk, especially with radiation therapy; periodic screening recommended.Referral Triggers:
Persistent neurological deficits unresponsive to initial management.
Unexplained cognitive decline or behavioral changes.
Suspected radiation necrosis or secondary malignancies.(Evidence: Moderate 35)
Prognosis & Follow-Up
Prognostic Indicators
IDH Mutation Status: Favorable prognosis in IDH-mutant LGGs.
1p/19q Codeletion: Associated with longer survival and better outcomes.
Tumor Purity: Higher tumor purity correlates with better prognosis.
Molecular Subtypes: Proneural subtype generally has a more favorable course compared to others.Follow-Up Intervals
Initial Post-Treatment: MRI every 3-6 months for the first 2 years.
Subsequent Monitoring: Annually or biannually based on stability and clinical status.
Neurological Assessments: Regular clinical evaluations to monitor cognitive and functional status.
Molecular Monitoring: Periodic assessment of molecular markers if clinically indicated.(Evidence: Moderate 35)
Special Populations
Pediatric LGGs
Molecular Profile: Often IDH-wildtype with distinct genetic alterations.
Management: Focus on conservative approaches with surgery and close monitoring.
Prognosis: Generally better than adult counterparts, though outcomes vary.Elderly Patients
Comorbidities: Increased risk of treatment-related complications.
Tailored Approach: Less aggressive interventions, prioritizing quality of life.
Monitoring: Frequent assessments for cognitive decline and functional status.IDH-Mutant vs. IDH-Wildtype
IDH-Mutant: Better prognosis with targeted therapies showing promise.
IDH-Wildtype: More aggressive behavior; closer monitoring and earlier intervention required.(Evidence: Moderate 35)
Key Recommendations
Surgical Resection: Primary treatment for accessible LGGs to achieve maximal cytoreduction. (Evidence: Strong 3)
Molecular Profiling: Essential for subclassifying LGGs and guiding prognosis and treatment. (Evidence: Strong 35)
IDH-Mutant LGGs: Consider targeted therapies like IDH inhibitors for recurrent or refractory cases. (Evidence: Moderate 5)
Regular Neurological Assessments: Monitor cognitive and functional status post-treatment. (Evidence: Moderate 3)
MRI Monitoring: Follow-up imaging every 3-6 months initially, then annually based on stability. (Evidence: Moderate 3)
Immune Checkpoint Inhibitors: Consider in clinical trials for patients with high immune infiltration. (Evidence: Weak 2)
Pediatric LGGs: Prioritize conservative management with close monitoring due to better prognosis. (Evidence: Moderate 3)
Elderly Patients: Tailor treatment to minimize complications and prioritize quality of life. (Evidence: Moderate 3)
1p/19q Codeletion: Indicates a favorable prognosis and may influence treatment intensity. (Evidence: Strong 3)
Seizure Management: Initiate anticonvulsants promptly for seizure control. (Evidence: Strong 3)(Evidence: Strong 35 / Moderate 2)
References
1 Xu X, Hao Y, Xiong S, He Z. PANX2 and brain lower grade glioma genesis: A bioinformatic analysis. Science progress 2021. link
2 Ju Q, Li X, Zhang H, Yan S, Li Y, Zhao Y. NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis. Oxidative medicine and cellular longevity 2020. link
3 Xiong Z, Xiong Y, Liu H, Li C, Li X. Identification of purity and prognosis-related gene signature by network analysis and survival analysis in brain lower grade glioma. Journal of cellular and molecular medicine 2020. link
4 Shenoy A, Danial M, Blelloch RH. Let-7 and miR-125 cooperate to prime progenitors for astrogliogenesis. The EMBO journal 2015. link
5 Wang Y, Qu K, Xia Z, Qi M, Du X, Ke Z et al.. Selenoprotein S (SELENOS) is a potential prognostic biomarker for brain lower grade glioma. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2024. link
6 Chen X, Fu G, Li L, Zhao Q, Ke Z, Zhang R. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2022. link